Abstract 1938P
Background
Magnitude of clinical benefit from drugs used in tumours must be evaluated using validated and reproducible tools. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS) and American Society for Medical Oncology (ASCO) Value Framework (ASCO-VF) are the most important. Here, we evaluate characteristics and outcomes of clinical trials supporting drugs used in STS and BS, and their association with ESMO-MCBS and ASCO-VF.
Methods
We reviewed publications between January 1988 and December 2022 that support the recommendations of NCCN guidelines version 1.2023 for STS and 3.2023 for BS (gastrointestinal stromal tumours were excluded). We collected data regarding trial characteristics, efficacy, toxicity and quality of life (QoL). ESMO-MCBS and ASCO-VF were applied. Substantial clinical benefit was defined as a grade 4 or 5 (in a scale from 1 to 5) for ESMO-MCBS and a ≥45 for ASCO-VF.
Results
We identified 119 studies (71 for STS and 48 for BS) that support the use of 49 drugs or combinations. ESMO-MCBS could be applied in 58 trials (48.7%). Of them, 37 (64%) were single arm and 21 (36%) randomized clinical trials (RCT; 13 phase III and 8 phase II). ASCO-VF could only be applied in 10 of the previously described (6 phase III and 4 phase II RCT). QoL was reported in 17.2% (10/58), all published beyond 2011. Among these, only 1 (10%) showed improvement in QoL. Only 33.3% of RCT (7/21) demonstrated improvement in overall survival. Ten (17.2%) trials, all of them RCT, met the ESMO-MCBS substantial benefit threshold (7 involving STS and 3 BS). Only 4 of these met the ASCO-VF criteria (all for STS). Spearman’s correlation coefficient between scales was 0.65.
Conclusions
Less than half of the studies supporting the NCCN recommendations for the prescription of drugs in advanced sarcomas can be evaluated using validated scales to assess the magnitude of their clinical benefit. Substantial clinical benefit was only achieved in a minority of those. QoL analysis should be incorporated in further studies to better evaluate their actual clinical benefit. Correlation among ESMO-MCBS and ASCO-VF was noteworthy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15